

## HBRN Adult Immune Active Trial Bibliography

### Publications

Feld JJ, Wahed AS, Fried M, Ghany MG, Di Bisceglie AM, Perrillo RP, Khalili M, Yang X, Belle SH, Janssen HLA, Terrault N, Lok AS for the Hepatitis B Research Network (HBRN). [Withdrawal of Long-Term Nucleotide Analogue Therapy in Chronic Hepatitis B: Outcomes from the Withdrawal Phase of the HBRN Immune Active Treatment Trial](#). *Am J Gastroenterol*. 2023 Jan 13. doi: 10.14309/ajg.0000000000002176. Online ahead of print. PMID: 36728214.

Ghany MG, Belle SH, Kleiner DE, Smith C, Kelley SS, Rosenthal P, Fontana RJ for the Hepatitis B Research Network. [Safety and Yield of Percutaneous Liver Biopsy in Adults and Children with Chronic Hepatitis B: Results from a Prospective, Multicenter Study](#). *Hepatol Commun*. 2023;7:e0116. doi: 10.1097/HC9.000000000000116. PMCID: PMC10187861.

Kleiner DE, Lisker-Melman M, Wahed AS, Bhan AK, Nalesnik MA, Choi EK, Leonard KK, Ghany MG, Chung RT, Di Bisceglie AM for the HBRN. [Immunohistochemical Staining for Hepatitis B Viral Antigens in Liver Biopsies and Association with Clinical, Biochemical, and Virologic Features of Disease](#). *J Gastroenterol Hepatol*. 2023 Mar 8. doi: 10.1111/jgh.16167. Online ahead of print. PMID: 36890337.

Terrault NA, Lok AS, Wahed AS, Ghany MG, Perrillo RP, Fried MW, Wong DK, Khalili M, Lau DTY, Sterling RK, Di Bisceglie AM, Lisker-Melman M, Cooper SL, Chung RT, Patel K, Roberts LR, Belle SH, Janssen HLA for the Hepatitis B Research Network. [Randomized Trial of Tenofovir With or Without Peginterferon Alfa Followed by Protocolized Treatment Withdrawal in Adults With Chronic Hepatitis B](#). *Am J Gastroenterol*. 2023 Jan 5. doi: 10.14309/ajg.0000000000002125. Online ahead of print. PMID: 36599136.

In addition, the HBRN has had the following presentations at national and international meetings

### **American Association for the Study of Liver Diseases (AASLD)**

#### AASLD 2020

Terrault N, Lok AS, Wahed AS, Wong DKH, Khalili M, Fried MW, Lau D, Ghany MG, Sterling RK, Di Bisceglie AM, Perrillo RP, Lisker-Melman M, Cooper S, Chung RT, Patel K, Roberts LR, Landis C, Hassan MA, Aoki CA, Belle S, Janssen HLA. **Randomized Trial of 192 Weeks of Tenofovir With or Without Peginterferon Alfa for the First 24 Weeks Followed by Protocolized Withdrawal in Adults with Chronic Hepatitis B**. *Hepatology* 2020; 72 (Suppl. 1):15A-16A.

#### AASLD 2021

Evon DM, Lin HS, Wahed A, Khalili M, Fontana RJ, Hoofnagle JH. **Symptoms of Liver Disease During Tenofovir Therapy With or Without Peginterferon: Results from the Hepatitis B Research Network Immune Active Trial**. *Hepatology* 2021; 74 (Suppl. 1):498A.

Feld JJ, Wahed A, Ghany MG, Khalili M, Terrault N, Perrillo RP, Di Bisceglie AM, Fried MW, Belle S, Janssen HLA, Lok AS. **Treatment Withdrawal After Long-Term Nucleotide Analogue Therapy With or Without Peginterferon: Predictors of ALT Flares, HBsAg Decline, and Active Disease**. *Hepatology* 2021; 74 (Suppl. 1):501A-502A.

Perrillo R, Lok AS, Leonard K, Ghany M, Terrault N, Belle SH, Janssen HLA. **The Relationship Between ALT Flares and HBV Antigen Kinetics During Treatment with Tenofovir (TDF) Monotherapy vs. Peginterferon (PEGIFN) Plus TDF**. *Hepatology* 2021; 74 (Suppl. 1):501A.

Terrault N, Lok AS, Wahed A, Ghany MG, Perrillo RP, Fried MW, Wong DKH, Khalili M, Lau D, Sterling RK, Di Bisceglie AM, Lisker-Melman M, Cooper S, Chung RT, Patel K, Roberts LR, Landis C, Aoki CA, Hassan MA, Belle S, Hoofnagle JH, Janssen HLA. **Effects of HBV Subgenotype A2 and an Initial 24-week Course of Peginterferon on Outcomes with Longer-Term Tenofovir: The Multicenter HBRN Immune Active (IA) Trial**. *Hepatology* 2021; 74 (Suppl. 1):479A.